Business Wire

Blackmoor Investment Partners Strengthens Its PE Capabilities as It Attracts Investment and Expands Its Senior Team to Pursue Ambitious Growth Plans

Share

Blackmoor Investment Partners (“Blackmoor”), a long-term equity investor and active owner of high quality European public companies with significant improvement potential, has attracted investment from and appointed Alex Savin as Senior Partner.

Blackmoor was founded by Douglas Smith and Guido Schmidt-Chiari in 2017 to deliver superior returns to its investors by deploying private equity best practices to implement value creation strategies at its investee companies. Since inception, it has made over 25 core investments, having initiated and implemented change programs across its portfolio, significantly outperforming relevant benchmarks.

Alex Savin brings extensive private equity experience, having worked at Bain & Company’s Private Equity practice in London and Boston, and co-founding one of the most successful private equity firms in Central and Eastern Europe, which was backed by global institutional investors and delivered outstanding results. Prior to joining Blackmoor, he led Chrome Capital, an investment firm operating across Europe and the US. Savin will now fully dedicate his time to broadening and expanding Blackmoor’s model and scaling its business. With Savin on board, Blackmoor’s senior team aims to build on past successes and enhance its distinct private equity approach to public investments to become a partner of choice for global investors looking to generate outsized returns in Europe.

Douglas Smith, Senior Partner remarked: "Alex has been a key adviser to our firm for several years. His appointment is transformational for Blackmoor and signals our intent to further strengthen our core private equity approach to public market investments. In our role as a strategic reference shareholder, Blackmoor works with companies and fellow shareholders to unlock operational improvements, strengthen governance and facilitate strategic M&A to realise our companies’ full potential. Our ability to tap into Alex’s impressive 30+ year track record and networks will be invaluable as we deepen our private equity capabilities in origination, engagement, through to exit.”

Alexander Savin, Senior Partner remarked: "I am thrilled to be joining Blackmoor due to the strength of our senior bench, our track record and the opportunities that lie ahead to grow the business. Our high conviction, thematic-based strategy will enable us to capitalise on numerous opportunities in our markets. I look forward to helping to expand Blackmoor’s private equity capabilities and its potential to generate superior returns to a broader pool of investors across Europe, the US and globally.”

For enquiries: https://Blackmoorip.com or contact enquiry@blackmoorip.com

About Blackmoor

Blackmoor Investment Partners is a long-term investor and an active owner of a limited number of strategic minority stakes in high quality European public companies with significant value creation and M&A potential.

We seek to deliver superior long-term returns for our investors by engaging with Boards and Management of our investee companies to unlock value though improvements in strategy, operations, capital structure, investor relations and execution of strategic M&A opportunities.

Blackmoor Investment Partners Limited is authorised and regulated by the FCA.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241104597569/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

LumiThera Obtains FDA Authorization of Valeda Treatment for Dry AMD Patients to Improve Vision4.11.2024 23:18:00 CET | Press release

LumiThera Inc., a medical device company offering photobiomodulation (PBM) treatment for ocular damage and disease, today announced the U.S. Food & Drug Administration (FDA) has authorized marketing of Valeda® Light Delivery System for treatment of patients with dry age-related macular degeneration (AMD), a leading cause of central vision loss in people over 55 in developed countries. The Valeda therapy is the first ever authorized treatment by the FDA for vision loss in dry AMD patients. Valeda provides an improvement in best corrected visual acuity (BCVA) over 24 months of >5 letters or equivalent to a line on the eye chart. In the pivotal U.S. LIGHTSITE III trial, the Valeda treatment met its primary endpoint and was shown to be safe and effective in increasing and maintaining improved visual acuity. LumiThera submitted the US LIGHTSITE III clinical data as part of a technical package to the FDA under a De Novo request with special controls. “The De Novo authorization established Va

Shelley Gandhi Joins Firm – Headlines ELIQUENT’s Expanded Pharmacovigilance Service Offerings4.11.2024 20:50:00 CET | Press release

ELIQUENT Life Sciences (ELIQUENT), a global regulatory consulting firm, today announced that internationally recognized pharmacovigilance (PV) expert Shelley Gandhi has joined the firm. This strategic addition to ELIQUENT’s robust team of regulatory and quality leaders reinforces the firm’s commitment to delivering integrated solutions that streamline compliance, manage risk, and accelerate time-to-market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241104361511/en/ Shelley Gandhi joins ELIQUENT Life Sciences - bolsters expanded Pharmacovigilance & Risk Management Solutions (Photo: Business Wire) “Shelley’s firsthand knowledge of regulatory expectations and her proficiency in navigating complex regulatory challenges will be instrumental in expanding ELIQUENT’s pharmacovigilance solutions to meet the growing global demand for comprehensive safety and risk management across diverse markets,” said Tim Dietlin, Chief Executiv

Earnix Survey Reveals Majority of Insurers Plan to Implement AI Predictive Models Within Two Years4.11.2024 17:10:00 CET | Press release

After years of uncertainty, majority of Insurers are ready to take the next steps to implement more effective strategies to grow their business Earnix, the leading AI, real-time platform for intelligent decisioning SaaS solutions for the insurance and financial services industries, today announced its third annual survey on the state of the insurance market, the 2024 Industry Trends Report. The survey of over 400 global insurance executives uncovers key findings, trends, implications for what’s next in insurance, and sheds light on the role technology can play in shaping a better future. Key findings from the 2024 survey include: More than two-thirds (70%) of respondents expect to deploy AI models that make predictions based on real-time data in the next two years More than half of respondents (51%) report their company had to pay a fine or issue refunds due to errors in the last year 58% of respondents take more than 5 months to implement a rule change and 21% take longer than 7 month

Parse Biosciences Launches Evercode Low Input Fixation for Cells and Nuclei4.11.2024 17:00:00 CET | Press release

New kits require low input and provide added flexibility and performance for single cell researchers Parse Biosciences, a leading provider of accessible and scalable single cell sequencing solutions, today announced the launch and availability of Evercode™ Low Input Fixation kits for both cells and nuclei. The new kits empower researchers who have a small number of starting cells or nuclei who ordinarily might not be able to perform single cell sequencing using fixed cells. Fixation is a strategy used by many single cell researchers because it enables them to collect samples at different times and then perform library preparation and sequencing at once when all of the samples are amassed. Yet, a well-known challenge across all fixation technologies is that they require a certain number of cells or nuclei, usually 50,000 or greater. With the new kits from Parse, researchers can start with as few as 10,000 cells or nuclei. The new low input fixation kits are ideal for researchers working

Omdia, Leading Market Research Firm, Reveals Significant Bottom Line Returns in Video Analytics Investments4.11.2024 15:00:00 CET | Press release

Independent study by Omdia, commissioned by BriefCam, finds over 85% of organizations achieve exponential ROI within one year BriefCam®, a leader in innovative, AI-driven video analytics solutions, today announced the results of a groundbreaking independent study on the return on investment (ROI) of video analytics technology. The research, conducted by Omdia and commissioned by BriefCam, reveals that an overwhelming majority of organizations experience a return on their video analytics investment within the first year of implementation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241104937597/en/ Vendor agnostic market research report on the return on investment of video analytics. (Graphic: Business Wire) Key findings from the report include: Over 85% of surveyed end users achieved ROI from their video analytics solution within one year 69% of end users agreed that their video analytics solution was a worthwhile financi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
HiddenA line styled icon from Orion Icon Library.Eye